PAVmed Inc. is a highly-differentiated multi-product medical device company.  The Company's product pipeline includes NextFlo, a disposable infusion pump; PortIO, a long-term implantable vascular access device; Caldus, a disposable tissue ablation device; CarpX, a percutaneous device to treat carpal tunnel syndrome; and NextCath, a self-anchoring short-term catheter. In addition to its lead projects, PAVmed is working on projects which are currently in the conceptual phase. These additional projects cover a wide range of clinical conditions and procedures, including sleep apnea, extracorporeal membrane oxygenation, laparoscopic hernia repair, cardiac surgery, interventional cardiology and endotracheal intubation.

Type
Public
HQ
Queens, US
Founded
2014
Size (employees)
3 (est)+50%
Website
pavmed.com
PAVmed was founded in 2014 and is headquartered in Queens, US
Report incorrect company information

PAVmed Office Locations

PAVmed has an office in Queens
Queens, US (HQ)
4600 251-1 Grand Central Parkway Service Road
Show all (1)
Report incorrect company information

PAVmed Financials and Metrics

PAVmed Financials

USD

Net income (Q3, 2017)

(5.1 m)

EBIT (Q3, 2017)

(2 m)

Market capitalization (31-Oct-2017)

58.8 m

Closing share price (31-Oct-2017)

4.5

Cash (30-Sep-2017)

3.1 m
PAVmed's current market capitalization is $58.8 m.
Annual
USDFY, 2016

General and administrative expense

1.1 m

R&D expense

607 k

Operating expense total

1.7 m

Net Income

(5.7 m)
Quarterly
USDQ2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

General and administrative expense

1.5 m1.3 m1.3 m

R&D expense

656.7 k701.7 k704.9 k

Operating expense total

1.3 m1.9 m2.2 m2 m2 m

Depreciation and amortization

5.3 k
Annual
USDFY, 2016

Cash

585.7 k

Accounts Receivable

82.3 k

Inventories

155.5 k

Current Assets

741.2 k
Quarterly
USDQ2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Cash

3 m1.8 m905.7 k82.1 k3.1 m

Inventories

103.3 k

Current Assets

3.1 m2 m1.1 m206.7 k3.2 m

Total Assets

3.2 m2 m1.1 m226.5 k3.2 m
Annual
USDFY, 2016

Net Income

(5.7 m)

Depreciation and Amortization

3.8 k

Inventories

(146.7 k)

Accounts Payable

877.6 k
Quarterly
USDQ2, 2016Q3, 2016Q1, 2017

Net Income

(1.3 m)(1.9 m)(4.3 m)

Accounts Payable

216.1 k609.9 k934.2 k
USDY, 2017

Financial Leverage

-0.5 x
Show all financial metrics
Report incorrect company information